Rockefeller Capital Management
ZVRA icon

Rockefeller Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Rockefeller Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.38K Sell
375
-418
-53% -$4.65K ﹤0.01% 4219
2026
Q1 		$7.39K Buy
793
+634
+399% +$5.71K ﹤0.01% 4114
2025
Q4 		$1.43K Buy
+159
New +$1.5K ﹤0.01% 4389
2021
Q3 		– Sell
-125
Closed -$1K – 3875
2021
Q2 		$1K Sell
125
-100
-44% -$1.07K ﹤0.01% 3391
2021
Q1 		$2K Buy
+225
New +$1.97K ﹤0.01% 3129
2020
Q3 		– Sell
-125
Closed -$1K – 2835
2020
Q2 		$1K Hold
125
– – ﹤0.01% 2518
2020
Q1 		$0 Buy
+125
New +$691 ﹤0.01% 2505

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rockefeller Capital Management's ZVRA Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Zevra Therapeutics (ZVRA) stake by 53% in Q2 2026, selling an estimated $4.65K and leaving 375 shares worth $5.38K. The position accounts for ﹤0.01% of the portfolio, ranked #4219.

Rockefeller Capital Management first reported a position in ZVRA in Q1 2020 and has held it in 7 quarters since. The position peaked at $7.39K in Q1 2026. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Rockefeller Capital Management held 375 shares of Zevra Therapeutics worth $5.38K as of Q2 2026.
  • Rockefeller Capital Management sold 418 Zevra Therapeutics shares in Q2 2026, an estimated $4.65K.
  • Zevra Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4219 holding.
  • Rockefeller Capital Management first reported a position in Zevra Therapeutics in Q1 2020 and has held it in 7 quarters since.
  • Rockefeller Capital Management's Zevra Therapeutics position peaked at $7.39K in Q1 2026.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.